2026-P: Efficacy of Internet-Based Intensive Weight Management or Exenatide Treatment on Weight Loss and Metabolism in Overweight/Obese PCOS

Abstract

To evaluate efficacy of internet-based intensive weight management or exenatide treatment on weight loss and metabolism in overweight/obese patients with polycystic ovary syndrome(PCOS). The study recruited 50 overweight/obese patients with PCOS into intensive lifestyle intervention group(ILI) for internet-based intensive weight management, which characterized with strict-energy and low-carbohydrate diets(1100-1400 kcal of total energy and less than 50g of carbohydrates per day), nutritional meal-replacement diets for lunch and dinner, online reporting followed by nutrionists, exercises, behavioral intervention and medication(metformin, 500mg Tid), for 3 months. 50 BMI matched subjects assigned to 3 months of exenatide injection (10μg bid)in our previous study were recruited as control group (EXE group). Oral glucose tolerance test were performed to assess glucose tolerance and insulin sensitivity. Anthropometric, glycolipid metabolic markers, sex hormone level and inflammatory state were measured and compared between two intervention. After 3 months of intervention, decreases of weight(ILI group 10.02 ± 3.06 kg vs. EXE group 6.15 ± 2.28 kg), BMI (ILI group 3.98±1.26 kg/m2 vs. EXE group 2.54±1.05 kg/m2), HOMA-IR(2.60 ± 2.37 vs. 1.06 ± 2.04), WC, FBG, FINS, TG and UA in ILI group were more statistically significant than EXE group. There were no significant differences in decreases of 2hPBG, 2hINS, testosterone and hs-CRP between two groups(P> 0.05). There were no statistically differences in improvements of total cholesterol, LDL-C, ALT, and AST in both groups (P> 0.05). It is suggested that internet-based intensive weight management in overweight/obese PCOS can significantly reduce weight, improve central obesity and insulin resistance. These effects were significantly better than exenatide treatment. However there were no significant differences in improvements of testosterone level and inflammatory state. Disclosure S. Zheng: None. Y. Zhang: None. R. Li: None. J. Xue: None. H. Shen: None.